2-methyl-2-(3-((2-(4-methylbenzoyl)-1H-benzo[d]imidazol-1-yl)methyl)phenoxy)propanoic acid | 1290176-59-8

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: 2-methyl-2-(3-((2-(4-methylbenzoyl)-1H-benzo[d]imidazol-1-yl)methyl)phenoxy)propanoic acid
• 英文别名: 2-methyl-2-[3-[[2-(4-methylbenzoyl)benzimidazol-1-yl]methyl]phenoxy]propanoic acid
• CAS: 1290176-59-8
• 化学式: C₂₆H₂₄N₂O₄
• 分子量: 428.488
• InChiKey: ONJDXLUPSLUGAQ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  5.2
• 重原子数：
  32
• 可旋转键数：
  7
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.19
• 拓扑面积：
  81.4
• 氢给体数：
  1
• 氢受体数：
  5

反应信息

• 作为产物：
  描述：

  3-羟基苯甲醇 在 偶氮二甲酸二异丙酯 、 potassium carbonate 、 三苯基膦 、 三氟乙酸 作用下， 以 四氢呋喃 、 氯仿 为溶剂， 生成 2-methyl-2-(3-((2-(4-methylbenzoyl)-1H-benzo[d]imidazol-1-yl)methyl)phenoxy)propanoic acid
  参考文献：
  名称：

  Synthesis and pharmacological evaluation of novel benzoylazole-based PPAR α/γ activators

  摘要：

  In our search for new PPAR alpha/gamma agonists, we designed and synthesized a series of benzoylazole-based carboxylic acids. Compound 9 showed potent PPAR gamma partial agonistic activity with modest PPAR alpha agonistic activity. The sodium salt of 9 (9Na) demonstrated potent efficacy in lowering both blood glucose and lipids in an animal model without causing significant body weight gain, a well-known side effect associated with PPAR gamma full agonists. (C) 2011 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2011.02.032

文献信息

• Synthesis and pharmacological evaluation of novel benzoylazole-based PPAR α/γ activators
  作者：Kantaro Ushiroda、Katsunori Maruta、Takeshi Takazawa、Tomokazu Nagano、Mutsuo Taiji、Tetsuya Kohno、Yasuhiro Sato、Shinji Horai、Kazunori Yanagi、Ryu Nagata

  DOI：10.1016/j.bmcl.2011.02.032

  日期：2011.4

  In our search for new PPAR alpha/gamma agonists, we designed and synthesized a series of benzoylazole-based carboxylic acids. Compound 9 showed potent PPAR gamma partial agonistic activity with modest PPAR alpha agonistic activity. The sodium salt of 9 (9Na) demonstrated potent efficacy in lowering both blood glucose and lipids in an animal model without causing significant body weight gain, a well-known side effect associated with PPAR gamma full agonists. (C) 2011 Elsevier Ltd. All rights reserved.